Bednár J, Nĕmec J, Soutorová M, Neradilová M, Pohunková D, Zamrazil V, Vána S, Havelka J, Röhling S
Endocrinol Exp. 1979 Mar;13(1):53-63.
The levels of total organically bound 131I, per cent of labelled iodoproteins, total labelled iodinated amino acids and a percentage of individual iodinated amino acids (thin-layer chromatography) were measured in serum of 84 patients with thyroid cancer and of 16 patients with thyrotoxicosis at 48 h after the administration of therapeutic dose of 131I. In thyrotoxic patients treated with therapeutic doses of 131I (2 to 39.6mCi; 74 to 1500 MBq) the findings were similar to normal subjects. In patients with thyroid cancer a significant increase of iodotyrosines was found after thyroid radioiodide ablation (100 to 200 mCi; 3.7 to 7.4 GBq). No remarkable differences were found between two groups of patients with thyroid cancer, the first one being treated with thyroid eliminating dose in attempt to activate the metastases of functionally differentiated tumour, while the second one was treated with similar doses (i. e. 100 to 200 mCi) to suppressor destroy a functionally active tumour or its metastases. Even though the hormonogenesis in tumours was hardly distinguishable from the products of its radiation damage, it was suggested that the hormonogenesis in neoplastic tissue differs from that in normal thyroid only quantitatively, being less in patients with thyroid cancer than in these with thyrotoxicosis.
在给予治疗剂量的131I 48小时后，测定了84例甲状腺癌患者和16例甲状腺毒症患者血清中总有机结合131I的水平、标记碘蛋白的百分比、总标记碘化氨基酸以及单个碘化氨基酸的百分比（薄层色谱法）。在用治疗剂量的131I（2至39.6mCi；74至1500MBq）治疗的甲状腺毒症患者中，结果与正常受试者相似。在甲状腺癌患者中，甲状腺放射性碘消融后（100至200mCi；3.7至7.4GBq）发现碘酪氨酸显著增加。两组甲状腺癌患者之间未发现明显差异，第一组采用甲状腺消除剂量治疗以激活功能分化肿瘤的转移灶，而第二组采用相似剂量（即100至200mCi）治疗以抑制或破坏功能活跃的肿瘤或其转移灶。尽管肿瘤中的激素生成与其辐射损伤产物难以区分，但有人认为肿瘤组织中的激素生成与正常甲状腺组织中的激素生成仅在数量上有所不同，甲状腺癌患者的激素生成比甲状腺毒症患者少。
